Original investigation

Use of Electronic Cigarettes Leads to Significant Beta2-Nicotinic Acetylcholine Receptor Occupancy: Evidence From a PET Imaging Study

Stephen R. Baldassarri MD¹, Ansel T. Hillmer PhD^{2,3}, Jon Mikael Anderson MS³, Peter Jatlow MD^{4,3}, Nabeel Nabulsi PhD², David Labaree PhD², Kelly P. Cosgrove PhD^{2,3}, Stephanie S. O'Malley PhD³, Thomas Eissenberg PhD⁵, Suchitra Krishnan-Sarin PhD³, Irina Esterlis PhD³

¹Department of Internal Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT; ²PET center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT; ³Department of Psychiatry, Yale School of Medicine, New Haven, CT; ⁴Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT; ⁵Department of Psychology (Health Program) and Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, VA

Corresponding Author: Stephen R. Baldassarri, Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, 300 Cedar Street, TAC-441 South, New Haven, CT, 06520, USA. E-mail: stephen.baldassarri@yale.edu

Abstract

Background: Electronic cigarettes (ECs) can influence nicotine addiction by delivering aerosolized nicotine. We investigated if nicotine from ECs is delivered to the brain β_2^* -nicotinic acetylcholine receptors (β_2^* -nAChR) and how this relates to the behavioral effects and nicotine delivery from cigarettes.

Methods: Seven nicotine users participated in positron emission tomography (PET) studies with (-)-[18F]Flubatine before and after nicotine challenge with 0, 8, and 36 mg/ml nicotine in a 3.3 Volt, 1.5 Ohm EC or a standard tobacco cigarette. Craving was evaluated before and after product use.

Results: Average β_2^* -nAChR occupancy was higher after 36 mg/ml EC challenge compared to 8 mg/ml EC at trend level. Average β_2^* -nAChR occupancy after tobacco cigarette smoking was $68 \pm 18\%$ and was not different compared with 8 mg/ml ($64 \pm 17\%$) or 36 mg/ml ($84 \pm 3\%$) nicotine in EC users. Area under the curve (AUC) of blood nicotine level was higher in the cigarette smoking group compared with the 8mg/ml group ($p = 0.03$), but similar compared with the 36 mg/ml EC ($p = 0.29$). Drug craving was reduced after use of the tobacco cigarette, 8 mg/ml EC, and 36 mg/ml EC.

Conclusions: In this novel investigation of EC effects at β_2^* -nAChRs, we show that average β_2^* -nAChR occupancy was higher after 36 mg/ml EC challenge compared with 8 mg/ml EC. Receptor occupancy and arterial blood nicotine levels after cigarette smoking were similar to 36 mg/ml EC use under controlled conditions. These findings suggest that the ECs studied here have abuse liability and may provide an adequate alternative nicotine delivery system for cigarette smokers.

Implications: This is the first study to directly determine the neurologic effects of electronic cigarettes on human brain beta-2 nicotinic acetylcholine receptors using PET neuroimaging with (-)-[18F] Flubatine, a novel radiotracer. Our findings suggest that the e-cigarettes studied here have abuse liability and may provide an adequate alternative nicotine delivery system for cigarette smokers.

Introduction

Estimates suggest that tobacco cigarette smoking caused more than 20 million premature deaths since 1965 and is the most preventable cause of disease.¹ Although rates of dependence on nicotine, the primary addictive constituent of cigarette smoke, have stabilized at 15% for the general population in the U.S., nationwide smoking cessation rates continue to be low.² Inhalation is the quickest way a drug can reach the brain and provide neurological effects. Inhaled cigarette smoke delivers nicotine to the pulmonary circulation and reaches the arterial circulation and brain within seconds after inhalation, leading to a rapid neurologic effect and high abuse/dependence liability.³ Nicotine replacement products designed to increase cessation rates have been developed in the form of patches, gum, lozenges, nasal spray, and inhaler. However, they deliver nicotine more slowly compared to cigarette smoking and may not be as rewarding to smokers.⁴ Recently, electronic cigarettes (EC) have gained popularity among experienced cigarette smokers as well as tobacco-naïve users.⁵ However, scientific information about ECs to inform consumers has been limited due in part to rapidly evolving EC design features.

ECs are battery-operated devices that heat and aerosolize a liquid that typically contains propylene glycol, vegetable glycerin, flavorants, and the psychoactive drug nicotine. Although initial studies of early model ECs suggested that their ability to deliver nicotine was minimal,⁶ later studies with more advanced products found that some ECs can deliver nicotine to the venous blood in physiologically active doses and, in some cases, that EC-delivered nicotine is comparable to conventional cigarettes.^{7–10} Further, advances in product technology have led to the development of more sophisticated ECs (i.e. personal vaporizers) with larger batteries and tank systems that are capable of producing larger amounts of aerosol and greater nicotine delivery as compared to earlier EC products.^{7,9,11} ECs have the potential to engender and perpetuate nicotine dependence in non-users and youth, but may also have the potential to reduce harm in cigarette smokers.^{12,13} Identifying EC mechanisms of action in the brain, potential abuse liability, comparison to tobacco cigarettes, and the relationship between mechanism of action and user behavior are crucial steps in evaluating these products, understanding their effects, and proposing regulation that maximizes potential benefit while minimizing potential harm.

Nicotine binds with high affinity to the brain beta2 nicotinic acetylcholine receptors (β_2^* -nAChRs), which upregulate (increase in number) after chronic nicotine use.^{14,15} Receptor imaging with single photon emission computed tomography (SPECT) or PET has been used successfully to examine mechanisms of nicotine dependence through evaluation of β_2^* -nAChR availability as a consequence of cigarette smoking^{4,16,17} as well as occupancy by nicotine in multiple previous studies.^{15,18,19} Findings from these studies suggest that cigarette smokers maintain near complete receptor occupancy throughout the day,^{4,18,19} and that lower receptor occupancy levels lead to craving.⁴ No previous studies have determined the degree to which ECs deliver nicotine to the human brain.

The primary aim of this study was to use PET imaging and (-)-[18F]Flubatine to evaluate the amount of nicotine delivered to brain β_2^* -nAChRs and arterial blood from EC users puffing from a single cartomizer-type EC (3.3 Volt; 1.5 Ohm) loaded with one of three different concentrations of nicotine liquid (0, 8, and 36 mg/ml). We hypothesized that nicotine delivery to brain and blood (as measured by β_2^* -nAChR occupancy and arterial nicotine concentrations) would be greater in the higher active nicotine concentration liquid

compared to the lower or zero concentration liquid. We also hypothesized that higher nicotine delivery would result in higher ratings of product liking and wanting, subjective responses that can reflect abuse liability.²⁰ As an exploratory aim, we compared receptor occupancy and arterial blood nicotine levels of the EC users to tobacco cigarette smokers.

Methods

Participants

This study was approved by the Yale Institutional Review Board, Radioactive Drug Research Committee and by the Yale-New Haven Hospital Radiation Safety Committee. Four experienced EC users and 3 cigarette smokers participated in the study. After completing informed consent, subjects had a physical and neurological examination and an electrocardiogram (EKG). Lab tests were performed to exclude medical complications. Inclusion criteria were: (1) Men and women, aged 18–60 years, (2) Able to read and write English, (3) Able to give voluntary, written informed consent, (4) Daily EC use for at least 1 month among EC subjects or smoked >10 cig/day for the past year for cigarette smokers; (5) Urine cotinine levels > 50 ng/ml at intake; (6) CO levels > 7 ppm at intake for smokers; (7) non-treatment seeking. Exclusion criteria were: (1) Current medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology; (2) History of or current neurological or psychiatric disorder including drug or alcohol dependence (as per DSM-IV) except nicotine dependence; (3) Regular or current use of any prescription, herbal or illegal psychotropic medications in the past 1 year, with no current illegal drug use confirmed by urine toxicology; (4) Drink more than 21 drinks per week for women or 35 drinks per week for men;²¹ (5) Women who are pregnant or nursing; (6) Individuals currently taking medication that may affect cholinergic system or nicotine replacement therapy prescribed for smoking cessation; (7) Contraindications to MRI such as claustrophobia or metal in their body.

Clinical Assessments

A standardized battery was administered to all subjects for diagnostic purposes at intake including the Structured Clinical Interview for DSM-IV Disorders (SCID),²² and assessments of demographics, measures of tobacco use, alcohol and drug use, family history of smoking, mood (Beck Depression Inventory,²³ Center for Epidemiologic Studies Depression Scale²⁴), anxiety (State Trait Anxiety Inventory²⁵), impulsivity (Barratt Impulsivity Scale²⁶), smoking dependence (FTND²⁷), smoking/EC craving (Questionnaire on Smoking Urges Brief (QSU²⁸ subscales of intention/desire to smoke and urge for relief of negative affect²⁹ and adapted for ECs) and withdrawal (Nicotine Withdrawal questionnaire³⁰). Product liking and the Drug Effects Questionnaire³¹ were assessed on a subjective scale (0–100, low–high) immediately following product use.

Nicotine Abstinence

All participants were helped to remain abstinent for 5 days prior to each PET scan with contingency management techniques that have been used extensively in our laboratory.^{15,16,32} Specifically, we met with subjects on a daily basis over the 5 days of abstinence to provide support and obtain CO and urine cotinine levels to ensure smoking abstinence. Subjects were permitted to return to smoking/EC use as usual after each PET scan and repeat smoking cessation/EC abstinence prior to subsequent PET scans.

Imaging Procedures

Prior to the PET scans, a T1-weighted MRI was acquired for all subjects on a 3.0 Tesla Siemens Trio camera (Siemens, Erlangen, Germany) to rule out any brain abnormalities and for use in the delineation of regions of interest. A high resolution, three-dimensional Magnetization Prepared Rapid Acquisition Gradient Echo (MPRAGE) T1-weighted sequence was used to acquire sagittal images for anatomical determinations and co-registration (TR = 1500 ms, TE = 2.83 ms, FOV = 256 × 256 mm², matrix = 256 × 256 mm², slice thickness = 1.0 mm without gap, 160 slices, voxel size 1.0 × 1.0 × 1.0 mm³).

PET data were acquired on the Siemens High Resolution Research Tomograph (HRRT), the highest sensitivity and resolution human brain PET scanner.³³ A 6-minute transmission scan was acquired to correct for attenuation. List-mode data were reconstructed with OSEM with built-in corrections for attenuation, normalization, scatter, randoms, deadtime and subject motion.^{34,35} The radiotracer (-)-[18F]Flubatine was synthesized³⁶ and administered on PET scan days as a bolus plus constant infusion with a K_{bol} of 360 min over 3.5 h. The total injected [18F]Flubatine dose was not statistically different between subjects undergoing similar scans (0 mg/ml EC: 294 ± 4 mBq; 8 mg/ml EC: 276 ± 17 mBq; 36 mg/ml EC: 262 ± 21 mBq; Tobacco Cigarette: 200 ± 17 mBq ($p = 0.076$)). Injected cold mass was not different between subjects undergoing similar scans (0 mg/ml EC: 0.10 ± 0.089 µg; 8 mg/ml EC: 0.30 ± 0.25 µg; 36 mg/ml EC: 0.17 ± 0.17 µg; Tobacco Cigarette: 0.18 ± 0.19 µg ($p = 0.665$)). Specific activity of [18F]Flubatine was: 0 mg/ml EC - 2028 ± 155 mBq/nmol; 8 mg/ml EC - 572 ± 572 mBq/nmol; 36 mg/ml EC - 1299 ± 881 mBq/nmol; Tobacco cigarette - 909 ± 688 mBq/nmol. Arterial blood samples were taken to measure the metabolite-corrected parent [18F]flubatine input function as previously described³⁷ and nicotine concentration post challenge ($t = 0, 0.3, 1, 3, 5, 10, 20, 30, 60, 90$ min). Baseline receptor availability measure was obtained 90–120 min after radiotracer infusion as previously validated.³⁸ Subjects started a challenge [ECs (counterbalanced order) or tobacco cigarette] at 125 min for 5 min in the scanner. Post-nicotine scanning continued until the end of 210 min of infusion. The time period used to quantify occupancy was 180–210 min (55–85 min post challenge). A representative time activity curve of [18F]Flubatine in an EC user is shown in Figure 1. Subjects were given at least 2 weeks between each scan to allow for smoking or EC use resumption/cessation and arterial line healing. EC users participated in 2 scans (8 mg/ml and 36 mg/ml EC; $N = 2$) or 3 scans (0, 8 and 36 mg/ml; $N = 2$), while cigarette smokers participated in 1 scan (tobacco cigarette only).

Figure 1. Time activity curve of [18F]Flubatine in a representative EC user. 55–85 min post-nicotine challenge was sufficient to reach a new steady state and allow calculation of receptor occupancy.

Image Analysis and Outcome Measure

The primary outcome measure for this study was (-)-[18F]flubatine volume of distribution (V_T), estimated using the equilibrium ratio between total radioactivity concentration in brain and parent (-)-[18F]flubatine concentration in arterial plasma. This is proportional to the number of β_2^* -nAChRs available for (-)-[18F]flubatine binding, thus we refer to this as “receptor availability”. Baseline receptor availability was measured 90–120 min after radiotracer infusion. Subjects started a challenge [ECs (counterbalanced order) or tobacco cigarette] at 125 min for 5 min in the scanner. The time period used to quantify occupancy was 180–210 min (55–85 min post challenge). Post-nicotine scanning continued until the end of 210 min of infusion. Occupancy of β_2^* -nAChRs by nicotine was evaluated using the Lassen plot approach.³⁹ The regions of interest used for calculation of receptor occupancy were: cerebellum, frontal, parietal, temporal, occipital, caudate, putamen, hippocampus, and amygdala. These regions were used because they were previously examined in β_2^* -nAChR studies.^{4,18,37,38} Since there were no between-region differences in nicotine occupancy or physostigmine induced displacement by ACh,^{37,38} we did not focus on any particular region and assumed uniform uptake of nicotine from the ECs and tobacco cigarettes in this study. The thalamus was not included because equilibrium was not reached in this region with the bolus-infusion paradigm. Lassen plots in representative subjects are in Figure 2.

Use of EC

Based on the findings of recent studies that showed use of ECs led to similar venous plasma nicotine levels as cigarette smoking within 5 min of use,^{8,9,10} we used an e-Go type EC battery (3.3 V, 1000 mAh) with 1.5 ohm dual-coil 510-style cartomizer and a 70/30 propylene glycol/vegetable glycerin e-liquid (“tobacco flavor”) with nicotine concentration of 0 mg/ml ($n = 2$), 8 mg/ml ($n = 4$) and 36 mg/ml ($n = 4$). E-liquid nicotine concentrations were measured with a validated liquid chromatography tandem-mass spectrometry (LC-MS/MS) method with a linear range of 0.5 to 50 mcg/mL. Initially, a 0.050 mL aliquot of each liquid was diluted 1000-fold in acetonitrile, along with the addition of a stable isotopically labeled internal standard (nicotine-d4). This sample was further processed and injected (0.010 mL) into the LC-MS for quantitative analysis. Quantification was determined with a linear, 1/X weighting regression model using peak area ratios (nicotine peak area/nicotine-d4 peak area) versus concentrations.

Subjects were instructed to puff on the EC once every 30 s for 5 min (10 puffs total) in a manner as they normally would. A training session to familiarize EC users with the EC product used in the study was conducted at an appointment prior to the PET scans. All users were directly observed during EC use to ensure they did not have any problems operating the device.

Use of Tobacco Cigarettes

Cigarette smokers were provided with a standard cigarette (Camel, Turkish and Domestic blend) and instructed to take one puff every 30 s for 5 min (10 puffs total) in a manner as they normally would.

Blood Samples

On PET scan days, arterial blood samples were collected prior to radiotracer administration and at multiple time points after EC or cigarette use to determine nicotine and cotinine concentrations in the blood, which were assayed using liquid chromatography tandem-mass spectrometry with deuterated internal standards.⁴⁰

Figure 2. Lassen Plots for calculation of nicotinic receptor occupancy. The slope of the line corresponds to the receptor occupancy fraction. Top left: EC user #1 after 36 mg/ml EC; Top right: EC user #1 after 8 mg/ml EC; Bottom: smoker after tobacco cigarette.

Data Analysis

Statistical analyses were conducted using SPSS version 24. All outcomes were summarized descriptively, and nonparametric analyses were performed for all group comparisons. For comparison between cigarette smokers and EC users, the Mann-Whitney *U* test for independent samples was performed. For within group comparisons, the Wilcoxon Signed Rank test for related samples was performed. All tests were two-sided and considered statistically significant at $\alpha = 0.05$.

Results

Participants

Four healthy EC users participated in two scans each (8 mg/ml and 36 mg/ml EC), and two of the users underwent a third scan with a placebo (0 mg/ml EC). The mean age was 26 ± 4 years, and one subject was female. The baseline urine cotinine level was 875 ± 144 ng/ml, and the baseline exhaled carbon monoxide level was 6 ± 1 ppm. Three healthy smokers participated in one scan with cigarette challenge. The mean age was 45 ± 16 years, and one subject was female. The baseline urine cotinine level was 783 ± 385 ng/ml, FTND was 5.3 ± 2.5 and the baseline exhaled carbon monoxide level was 30 ± 28 ppm.

Occupancy and Arterial Blood Nicotine Levels Following EC Use

β_2^* -nAChR Occupancy by Nicotine

β_2^* -nAChR occupancy is summarized in Table 1, and V_T images from a subject who participated in three separate scans at different EC liquid nicotine concentrations (0, 8, and 36 mg/ml) are

shown in Figure 3. The average β_2^* -nAChR occupancy was higher after 36 mg/ml EC challenge compared with 8 mg/ml EC at trend level ($84 \pm 3\%$ vs. $64 \pm 17\%$, $p = 0.07$). The occupancy range was 41.6–81.9% after 8 mg/ml EC compared with 80.2–88.8% after 36 mg/ml EC. Two of the users achieved 70% occupancy following exposure to the 8 mg/ml EC condition. The use of the 0 mg/ml nicotine EC did not lead to significant receptor occupancy by nicotine ($2.5 \pm 5.5\%$).

Arterial blood Plasma Nicotine Levels

$C_{\max}$ and AUC from 0–90 min were higher after 36 mg/ml EC compared to 8 mg/ml EC at trend level (12 ± 5 ng/ml, 389 ± 137 ng*min/ml; and 6 ± 4 ng/ml, 175 ± 146 ng*min/ml, respectively; $p = 0.07$; Table 1 and Figure 4). No nicotine was detected in the plasma in the 0 mg/ml condition. $T_{\max}$ was not different following use of different ECs (8 mg/ml EC: 4.5 ± 1 min; 36 mg/ml EC: 5 ± 0 min).

Liking and Craving Ratings

Ratings of product liking were similar after each EC use (0 mg/ml = 80 ± 28 ; 8 mg/ml = 75 ± 38 ; 36 mg/ml = 74 ± 26). Craving was reduced at trend level as measured by the QSU brief scores²⁹ before and after use of 8 mg/ml EC [desire (13 ± 1 vs. 9 ± 3 ; $p = 0.07$) and the 36 mg/ml EC [desire (11 ± 3 vs. 8 ± 3 ; $p = 0.11$), relief (11 ± 6 vs. 9 ± 5 ; $p = 0.11$). Desire and relief were not significantly lower after the 0 mg/ml EC.

The change in desire and relief following challenge with the 8 mg/ml EC compared with the 36 mg/ml EC was not significantly different ($p = 0.29$). Subjective drug effects were similar across conditions.

Table 1. β_2^* -nAChR occupancy, maximum arterial blood nicotine concentration, and area under the curve after use of 8 mg/ml EC, 36 mg/ml EC, and tobacco cigarette

Subject No.	% Receptor occupancy after 8 mg/ml EC		% Receptor occupancy after 36 mg/ml EC		% Receptor occupancy after TOBACCO cigarette	V_{ND} average (ml/cm ³)	C_{max} (ng/ml) after 8 mg/ml EC		C_{max} (ng/ml) after 36 mg/ml EC		C_{max} (ng/ml) after TOBACCO cigarette	T_{max} (min) after 8 mg/ml EC	T_{max} (min) after 36 mg/ml EC	T_{max} (min) after TOBACCO cigarette	AUC (ng*min/ml) after 8 mg/ml EC	AUC (ng*min/ml) after 36 mg/ml EC	AUC after TOBACCO cigarette (ng*min/ml)	Average [NIC] 60–90 min after 8 mg/ml EC	Average [NIC] 60–90 min after 36 mg/ml EC	Average [NIC] 60–90 min after TOBACCO cigarette
	EC	EC	EC	EC	EC		EC	EC	EC	EC	EC	EC	EC	EC	EC	EC	EC	EC	EC	EC
1	41.6	83.6	N/A	N/A	N/A	6.00	2.9	17	N/A	N/A	N/A	3	5	N/A	123.7	457.9	N/A	0	2.7	N/A
2	64.3	80.2	N/A	N/A	N/A	6.30	4.2	5.9	N/A	N/A	N/A	5	5	N/A	61.5	224.4	N/A	0	1.9	N/A
3	80.9	88.6	N/A	N/A	N/A	6.27	11.1	12.5	N/A	N/A	N/A	5	5	N/A	389.5	537.0	N/A	2.7	3.7	N/A
4	70.2	84.0	N/A	N/A	N/A	6.77	5.9	13.1	N/A	N/A	N/A	5	5	N/A	126	336.0	N/A	0.5	2.1	N/A
5	N/A	N/A	N/A	N/A	N/A	6.79	N/A	N/A	29.3	N/A	29.3	N/A	N/A	5	N/A	N/A	625.2	N/A	N/A	4.0
6	N/A	N/A	N/A	N/A	N/A	5.67	N/A	N/A	25.3	N/A	25.3	N/A	N/A	5	N/A	N/A	498.3	N/A	N/A	2.7
7	N/A	N/A	N/A	N/A	N/A	7.43	N/A	N/A	26.7	N/A	26.7	N/A	N/A	5	N/A	N/A	425.3	N/A	N/A	2.1
AVERAGE	64.3 ± 17	84.1 ± 3	68.4 ± 18	64.6 ± 0.58	6.46 ± 0.58	6.46 ± 0.58	6 ± 4	12 ± 5	27 ± 2	4.5 ± 1	5 ± 0	5 ± 0	5 ± 0	175 ± 146	389 ± 137	516 ± 101	1.2 ± 1.7	2.2 ± 1.4	2.9 ± 0.97	

Exploratory Comparison of Occupancy and Arterial Blood Nicotine Levels Following EC and Cigarette Use

Receptor Occupancy by Nicotine

The average β_2^* -nAChR occupancy after the smoking challenge was $68.4 \pm 18\%$ (range 52.9–88.9%) and was not significantly different compared with the 8 mg/ml or 36 mg/ml EC ($p = 0.48$).

Arterial Blood Plasma Nicotine Levels

C_{max} following cigarette smoking was (27 ± 2 ng/ml), which was significantly higher than the C_{max} following EC use during both 8 and 36 mg/ml conditions (6 ± 4 ng/ml, vs. 12 ± 5 ng/ml; $p = 0.03$). AUC in the cigarette smoking group was 516 ± 101 ng*min/ml which was significantly higher compared AUC to the 8 mg/ml EC ($p = 0.03$) but not compared with 36 mg/ml EC ($p = 0.29$) in the EC group. T_{max} was 5 min for all trials (not different compared to EC use).

Liking and Craving Ratings

Liking following use of the tobacco cigarette was [37 ± 40]; this did not differ compared with the EC at either liquid strength (8 mg/ml: 75 ± 38 ; 36 mg/ml: 74 ± 26). Craving was lower, but not significantly, before and after cigarette smoking [desire (8 ± 3 vs. 5 ± 5 ; $p = 0.20$; relief (5 ± 2 vs. 3 ± 0 ; $p = 0.20$)). The change in score was not different after cigarette smoking compared with 8 mg/ml or 36 mg/ml nicotine solutions by the EC group.

Discussion

This study is the first to examine the in-vivo occupancy of nicotine at brain β_2^* -nAChRs in healthy EC users following exposure to three different nicotine concentrations (0, 8, and 36 mg/ml) administered using a 3.3 Volt, 1.5 Ohm EC. Preliminary results suggest that, under the conditions reported here, EC users can achieve brain β_2^* -nAChR occupancy similar to that of regular cigarette smokers, although nicotine levels in plasma tend to be lower. Furthermore, craving was reduced to a similar degree by use of ECs studied here and a tobacco cigarette.

Effects on β_2^* -nAChR Occupancy

The receptor occupancy levels in the cigarette smokers in our study ranged between 53–89% and were similar to levels noted previously.^{4,15,18,19} The smokers with lower receptor occupancy (subjects 6 and 7) were likely underestimated since one of them had a small amount of nicotine in the blood prior to scan and the other received a lower dose of injected radioactivity. The finding that experienced EC users who had used an EC with 8 mg/ml or 36 mg/ml liquid nicotine were capable of reaching receptor occupancy values similar to tobacco cigarette use provides further evidence of the abuse liability of ECs. Among the EC users, we note that there was greater consistency in receptor occupancy after use of the higher concentration nicotine liquid with all users ranging between 80–89%. There was more variability in receptor occupancy after use of the lower concentration nicotine liquid, but importantly, two of the subjects reached occupancy of 70% and 81% with this concentration. This finding indicates that, in the device reported here, use of 8 mg/ml nicotine is capable of providing tobacco smoke-like receptor occupancy, but that like cigarette smoking, user behavior is an important determinant of nicotine intake. Moreover, recent results from other laboratories suggest that even lower strength liquids (e.g., 4 mg/ml)

Figure 3. Parametric images at baseline and after use of different nicotine delivery systems in two representative subjects. The top row shows a tobacco cigarette smoker, and the bottom row shows an electronic cigarette user. (Top row left to right: Baseline, tobacco cigarette (89% occupancy); Bottom row left to right: Baseline, 36 mg/ml (84% occupancy), 8 mg/ml (41% occupancy), 0 mg/ml (no significant occupancy)).

Figure 4. Arterial blood nicotine concentrations after 5 min (10 puff) use of different nicotine delivery systems. Top left: 36 mg/ml EC; Top right: 8 mg/ml EC; Bottom: tobacco cigarette.

might be capable of similar effects, at least when paired with more powerful EC devices (e.g., 4 Volt, 0.4 Ohms).¹¹

Effects on Arterial Blood Nicotine Uptake

Cigarette smokers exhibited higher arterial blood nicotine C_{max} with less variability than EC users, which is consistent with prior studies suggesting that cigarette smoke delivers nicotine more efficiently than some ECs as measured by venous blood concentrations,⁴¹ but inconsistent with other studies that showed similar

uptake patterns.^{8,10,42} However, T_{max} and AUC were similar after cigarette use compared to 36 mg/ml EC use. These findings suggest similar brain nicotine delivery between these two products. We note, however, that puffing conditions were strictly controlled. The level of C_{max} and AUC individuals would have reached if they had puffed ad-lib or over a period of time longer than 5 min is unclear. Among cigarette smokers, the average C_{max} was lower than that previously observed,⁴ likely due to the limited duration and number of puffs permitted during the experiment. Whether these findings would remain consistent after ad lib (i.e. real-world) use of

the two products or in naïve users remains to be determined. Given the similarities between the products noted, the results suggest that the 36 mg/ml EC used here has the potential to perpetuate nicotine addiction but also to provide an effective nicotine delivery system for cigarette smokers.

When comparing within subject use of higher versus lower concentration liquid, there was a trend toward higher C_{max} and AUC after use of the high dose EC. Notably, even the lower concentration liquid was capable of delivering nicotine efficiently in some of these users. This result may suggest compensatory behavior (i.e. taking larger and/or longer puffs from the EC when lower concentration liquid was in it) in order to titrate to a desired nicotine level. The compensation phenomenon has been noted recently in EC users⁴³ and has been documented extensively in cigarette smokers.⁴⁴ Future studies with EC users may benefit from concurrent measurement of puff topography in order to explore this possibility.⁹

Effects on Product Liking/Craving

We hypothesized that liking would increase with higher nicotine strength liquids; however, we found no significant differences in product liking or wanting despite trends toward higher nicotine uptake following use of an EC with higher nicotine concentration liquid. Craving was also reduced to a similar degree across groups. There are several potential explanations for these findings. First, recent work has observed that perceived harshness of ECs increases with increasing nicotine strength and that menthol attenuates this effect.⁴⁵ Since we used a non-menthol “tobacco” flavored liquid, any potential increase in nicotine delivery may have been accompanied by an increase in harshness, which in turn could have attenuated liking and craving reduction. Future studies may consider the role of menthol and flavors in modifying product desirability, and particularly whether flavorants added to the liquid increase the appeal of liquids with higher nicotine concentrations. Second, other product characteristics may play a significant role in determining product acceptability. EC users were not using their preferred device and liquid, while cigarette smokers were not using their preferred cigarette brand. Since all users were using an unfamiliar product, it is probable that the differences in product liking and drug effects did not contribute significantly to the findings.

Study Limitations

This study has several limitations. First, only healthy EC users were enrolled and they were younger than the exploratory comparison group of cigarette smokers. The EC users were young and may not be as highly nicotine dependent as other populations. We therefore cannot generalize our findings to non-users who may initiate EC use, persons with medical and/or psychiatric comorbidities, more highly nicotine dependent persons, and older users. Second, the sample size was small. Because this study is preliminary, there remains the possibility that we were underpowered to detect differences between nicotine solution strengths with respect to liking and drug effects. Replication of this study with a larger sample size is necessary in order to validate the observed physiologic effects of EC use. Third, subjects puffed the ECs on a fixed schedule of one puff every 30 s for 5 min. It is possible that receptor occupancy, arterial blood, and subjective measures of product liking may have varied if subjects were permitted to puff ad-lib. Finally, we used a single EC device and a specific liquid formulation in a single flavor. ECs are a heterogeneous group of products that differ considerably across products in key factors such as battery voltage, heater resistance, materials, and

construction. Moreover, the nicotine liquids are also extremely variable, differing by propylene glycol/vegetable glycerin ratio, nicotine concentration, and flavorants added. Similarly, a standard tobacco cigarette was used that may not reflect the product characteristics to which users were previously accustomed. This could have affected all the biologic and subjective drug effects that were measured.

Future Directions

Another important question that remains (that could not be answered by this study) is whether equivalent nicotine receptor occupancy necessarily suggests equivalent abuse liability when comparing ECs to combustible tobacco products. While nicotine is the primary addictive component of tobacco, smoke contains more than 7000 chemicals when burned and is a much more complex mixture than EC aerosol.⁴⁶ Also, smoke constituents such as aldehyde products can potentiate the effects of nicotine by acting as MAO-I and reducing the metabolism of dopamine.⁴⁷ Future imaging studies examining these differences may provide important insights as to whether ECs are capable of equivalent dopamine release as compared to tobacco cigarettes.

Conclusions

The average β_2 -nAChR occupancy was higher after 36 mg/ml EC challenge compared with 8 mg/ml EC at trend level, but evidence of compensatory behavior was noted in two users under the 8 mg/ml condition. Cigarette smokers and EC users had similar β_2 -nAChR occupancy, T_{max} , and reductions in craving, while smokers reached higher maximal arterial blood nicotine concentrations after puffing under controlled conditions. AUC did not differ between tobacco smoking and use of the 36 mg/ml EC, indicating similar nicotine delivery to the brain and arterial blood. These findings suggest that the ECs studied here have abuse liability, but may also provide an effective nicotine delivery system for cigarette smokers. Undoubtedly, additional studies are required with a larger sample size and in different participant populations to expand our understanding of EC abuse liability and how they compare to traditional cigarettes.

Funding

Yale Tobacco Center of Regulatory Science / National Institute on Drug Abuse / Food and Drug Administration Center for Tobacco Products (P50DA036151-03S1, R01DA038832-01A1, K02DA031750), National Institute of Mental Health (K01MH092681), National Heart, Lung, and Blood Institute (T32HL007778). Dr. Eissenberg's effort is supported by P50DA036105.

Declaration of Interests

Dr. Eissenberg is listed as a co-inventor on a pending patent describing a device intended to measure puffing behavior in users of a variety of electronic cigarette products. There are no other relevant conflicts of interest.

Acknowledgments

We wish to thank the staff at the Yale PET Center for their imaging and chemistry expertise and help. We thank Ralitz Gueorgieva for her expertise and assistance with the statistical analyses. Research reported in this publication was supported by grant number P50DA036151-03S1 from NIDA and FDA Center for Tobacco Products (CTP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Food and Drug Administration.

References

1. National Center for Chronic Disease P, Health Promotion Office on S, Health. *Reports of the Surgeon General. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General*. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.
2. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. *JAMA*. 2014;311(2):193–194.
3. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. *Drug Alcohol Depend*. 1993;33(1):23–29.
4. Esterlis I, Mitsis EM, Batis JC, et al. Brain β_2^* -nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. *Int J Neuropsychopharmacol*. 2011;14(3):389–398.
5. McRobbie H, Bullen C, Hartmann-Boyce J, et al. Electronic cigarettes for smoking cessation and reduction. *Cochrane Database Syst Rev* 2014;12:Cd010216.
6. Eissenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. *Tob Control*. 2010;19(1):87–88.
7. Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. *Nicotine Tob Res*. 2013;15(1):267–270.
8. Lopez AA, Hiler MM, Soule EK, et al. Effects of Electronic Cigarette Liquid Nicotine Concentration on Plasma Nicotine and Puff Topography in Tobacco Cigarette Smokers: A Preliminary Report. *Nicotine Tob Res*. 2016;18(5):720–723.
9. Spindle TR, Breland AB, Karaoghlanian NV, Shihadeh AL, Eissenberg T. Preliminary results of an examination of electronic cigarette user puff topography: the effect of a mouthpiece-based topography measurement device on plasma nicotine and subjective effects. *Nicotine Tob Res*. 2015;17(2):142–149.
10. Ramôa CP, Hiler MM, Spindle TR, et al. Electronic cigarette nicotine delivery can exceed that of combustible cigarettes: a preliminary report. *Tob Control*. 2016;25(e1):e6–e9.
11. Wagener TL, Floyd EL, Stepanov I, et al. Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users. *Tob Control*. 2017;26(e1):e23–e28.
12. Hajek P, Etter JF, Benowitz N, Eissenberg T, McRobbie H. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. *Addiction*. 2014;109(11):1801–1810.
13. Breland A, Soule E, Lopez A, et al. Electronic cigarettes: what are they and what do they do? *Ann N Y Acad Sci*. 2017;1394(1):5–30.
14. Cosgrove KP, Batis J, Bois F, et al. beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. *Arch Gen Psychiatry*. 2009;66(6):666–676.
15. Esterlis I, Cosgrove KP, Batis JC, et al. Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of non-displaceable binding. *J Nucl Med*. 2010;51(8):1226–1233.
16. Cosgrove KP, Esterlis I, McKee SA, et al. Sex differences in availability of β_2^* -nicotinic acetylcholine receptors in recently abstinent tobacco smokers. *Arch Gen Psychiatry*. 2012;69(4):418–427.
17. Cosgrove KP, Batis J, Bois F, et al. beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. *Arch Gen Psychiatry*. 2009;66(6):666–676.
18. Brody AL, Mandelkern MA, Costello MR, et al. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. *Int J Neuropsychopharmacol*. 2009;12(3):305–316.
19. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. *Arch Gen Psychiatry* 2006;63:907–15.
20. Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK. Abuse liability assessment of tobacco products including potential reduced exposure products. *Cancer Epidemiol Biomarkers Prev*. 2009;18(12):3241–3262.
21. King AC, de Wit H, McNamara PJ, Cao D. Rewarding, stimulant, and sedative alcohol responses and relationship to future binge drinking. *Arch Gen Psychiatry*. 2011;68(4):389–399.
22. NINDS C. *Structured Clinical Interview for DSM-IV Axis Disorders Patient Version (SCID-I/P)*. Washington, DC: American Psychiatric Press; 1996.
23. Beck AT, Ward CH, Mendelson MM, et al. An inventory for measuring depression. *Arch Gen Psychiatry* 1961;4:561–571.
24. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. *Appl Psych Measure* 1977;1:385–401.
25. Knight RG, Waal-Manning HJ, Spears GF. Some norms and reliability data for the State-Trait Anxiety Inventory and the Zung Self-Rating Depression scale. *Br J Clin Psychol*. 1983;22 (Pt 4):245–249.
26. Barratt ES, Patton J, Stanford M. *Barratt Impulsiveness Scale*. Texas: Barratt-Psychiatry Medical Branch, University of Texas; 1975.
27. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. *Br J Addict*. 1991;86(9):1119–1127.
28. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. *Br J Addict*. 1991;86(11):1467–1476.
29. Toll BA, Katulak NA, McKee SA. Investigating the factor structure of the Questionnaire on Smoking Urges-Brief (QSU-Brief). *Addict Behav*. 2006;31(7):1231–1239.
30. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. *Arch Gen Psychiatry*. 1986;43(3):289–294.
31. Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O'Malley SS. The drug effects questionnaire: psychometric support across three drug types. *Psychopharmacology (Berl)*. 2013;227(1):177–192.
32. Esterlis I, Cosgrove KP, Batis JC, et al. GABAA-benzodiazepine receptor availability in smokers and nonsmokers: relationship to subsyndromal anxiety and depression. *Synapse*. 2009;63(12):1089–1099.
33. Hugo WAMdJ, Floris HPvV, Reina WK, et al. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. *Phys Med Biol* 2007;52:1505.
34. Carson RE, Barker WC, Liow J-S, et al. Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. In: Nuclear Science Symposium Conference Record, 2003 IEEE; October 19–25, 2003; Portland, OR. p. 3281–3285.
35. Jin X, Mulnix T, Gallezot JD, Carson RE. Evaluation of motion correction methods in human brain PET imaging—a simulation study based on human motion data. *Med Phys*. 2013;40(10):102503.
36. Brust P, Patt JT, Deuther-Conrad W, et al. *In vivo* measurement of nicotinic acetylcholine receptors with [18 F]norchloro-fluoro-homoepibatidine. *Synapse*. 2008;62(3):205–218.
37. Bois F, Gallezot JD, Zheng MQ, et al. Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([18F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates. *Nucl Med Biol*. 2015;42(6):570–577.
38. Hillmer AT, Esterlis I, Gallezot JD, et al. Imaging of cerebral $\alpha 4 \beta 2^*$ nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. *Neuroimage*. 2016;141:71–80.
39. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. *J Cereb Blood Flow Metab*. 2010;30(1):46–50.
40. Sofuoglu M, Herman AL, Nadim H, Jatlow P. Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. *Neuropsychopharmacology*. 2012;37(6):1509–1516.
41. Farsalinos KE, Spyrou A, Tsimopoulou K, et al. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. *Sci Rep* 2014;4:4133.
42. Talih S, Balhas Z, Eissenberg T, et al. Effects of user puff topography, device voltage, and liquid nicotine concentration on electronic cigarette nicotine yield: measurements and model predictions. *Nicotine Tob Res*. 2015;17(2):150–157.

-
43. Dawkins LE, Kimber CF, Doig M, Feyerabend C, Corcoran O. Self-titration by experienced e-cigarette users: blood nicotine delivery and subjective effects. *Psychopharmacology (Berl)*. 2016;233(15-16): 2933–2941.
 44. Ashton H, Stepney R, Thompson JW. Self-titration by cigarette smokers. *Br Med J*. 1979;2(6186):357–360.
 45. Rosbrook K, Green BG. Sensory Effects of Menthol and Nicotine in an E-Cigarette. *Nicotine Tob Res*. 2016;18(7):1588–1595.
 46. Kosmider L, Sobczak A, Fik M, et al. Carbonyl compounds in electronic cigarette vapors: effects of nicotine solvent and battery output voltage. *Nicotine Tob Res*. 2014;16(10):1319–1326.
 47. Benowitz NL. Nicotine addiction. *N Engl J Med*. 2010;362(24):2295–2303.